Top News

COVID-19 Vaccine Manufacturers Submit Appeals to FDA for Fourth Dose

March 21, 2022

Moderna, Pfizer, and BioNTech are seeking FDA approval for a fourth dose of their respective COVID-19 vaccines.

Ukraine Invasion Challenges Biopharma Research and Operations

March 11, 2022

Biotech companies and medical product manufacturers have condemned the invasion of Ukraine, while also looking to maintain supplies of essential medicines.

Voyager Therapeutics Announces License Agreement with Novartis Worth Up to $1.75 Billion

March 11, 2022

Novartis will pay Voyager up to $1.75 billion for access to Voyager’s novel Tracer AAV capsids for potential use with three CNS targets.

Life Science Executives Issue Call to Cut Business Ties with Russia

March 11, 2022

Various executives in the life sciences industry have started a petition calling for “complete economic disengagement” with Russia.

Biocon Biologics to Acquire Biosimilars Assets from Viatris in $3.3 Billion Deal

March 02, 2022

Biocon Biologics will acquire Viatris’ global biosimilars business, including the company’s portfolio of in-licensed biosimilar assets, in a transaction valued at over $3.3 billion.

Hovione Appoints Jean-Luc Herbeaux as New CEO

March 01, 2022

Hovione has announced that Jean-Luc Herbeaux will take over for Guy Villax as CEO on April 1, 2022.

Medicago and GSK Announce the Approval by Health Canada of COVIFENZ, an Adjuvanted Plant-Based COVID-19 Vaccine

February 24, 2022

Medicago and GSK have announced that Health Canada has approved COVIFENZ, an adjuvanted plant-based COVID-19 vaccine.

Novavax Begins Shipping its COVID-19 Vaccine to European Union Member States

February 23, 2022

Novavax announces the first doses of Nuvaxovid COVID-19 vaccine have begun shipping to European Union member states.

BioNTech Plans to Build Modular mRNA Manufacturing Facilities in Africa

February 21, 2022

The turnkey facilities will promote scalable vaccine production for an end-to-end manufacturing network for mRNA-based vaccines in Africa.

Lilly to Invest $1 Billion to Build New Parenteral Manufacturing Facility in North Carolina

February 02, 2022

Eli Lilly and Company is investing $1 billion to establish a new manufacturing site in Concord, NC, to manufacture parenteral products and devices.